Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
15 Juin 2023 - 10:01PM
Galapagos appoints Thad Huston as Chief Financial Officer and Chief
Operating Officer
Mechelen, Belgium;
15 June 2023,
22:01 CET; regulated
information – Galapagos NV (Euronext & NASDAQ: GLPG)
today announced the appointment of
Thad Huston as
Chief Financial
Officer
(CFO)
and Chief Operating
Officer
(COO) as
per 1 July 2023. Mr.
Huston will be a member of the Executive
Committee of Galapagos and
will join Galapagos from Kite, a Gilead
Company (NASDAQ: GILD).
He brings 30 years of global finance and
operational experience in healthcare with an excellent track record
of driving business transformation and innovation.
“On behalf of the Board of Directors and management of
Galapagos, I extend a warm welcome to Thad. Thad is a widely
recognized leader with a strong international network. Having spent
three decades in the healthcare sector, he brings with him a wealth
of experience and deep financial and operational know-how,” said
Dr. Paul Stoffels1, CEO and Chairman of Galapagos. “We are
convinced that Thad’s strategic and operational expertise,
including in cell therapy, is an excellent fit for our company as
we continue to execute on our R&D and business development
strategy in our focus areas of immunology and oncology.”
Thad Huston is currently Global Head of Finance and Corporate
Operations at Kite, the global leader in cell therapy. Before Kite,
Thad served as CFO of LivaNova (NASDAQ: LIVN), a publicly listed
medical devices company focused on neuromodulation with
presence in more than 100 countries. Prior to that role, he spent
over 25 years at Johnson & Johnson (J&J) (NYSE: JNJ) where
he held senior financial roles at various J&J locations in the
US, China, Belgium, Russia, and Hungary.
During his tenure at J&J, he helped establish the R&D
innovation model and played a key role in accelerating the product
pipeline through focused growth strategies, investments in
innovation, business development and streamlined productivity.
“I am very excited to join Galapagos and to work with Paul and
the team to realize the company’s full potential,” added Thad
Huston. “With its growing pipeline in oncology and immunology, a
European commercial infrastructure and a robust balance sheet, I
strongly believe that Galapagos has the fundamentals in place to
deliver on its mission to transform the lives of patients across
the globe, while creating value for its stakeholders.”
This press release contains inside information within the
meaning of Regulation (EU) No 596/2014 of the European Parliament
and of the Council of 16 April 2014 on market abuse (market abuse
regulation).
About GalapagosGalapagos is a fully integrated
biotechnology company united around a single purpose: to transform
patient outcomes through life-changing science
and innovation for more years of life and quality of
life. We focus on the key therapeutic areas of immunology and
oncology, where we have developed a deep scientific expertise in
multiple drug modalities, including small molecules and cell
therapies. Our portfolio comprises discovery through to
commercialized programs and our first medicine for rheumatoid
arthritis and ulcerative colitis is available in Europe and Japan.
For additional information, please visit www.glpg.com or
follow us on LinkedIn or Twitter.
Contacts
Media
relations contactMarieke
Vermeersch +32 479 490
603 media@glpg.com |
Investor
relations contact Sofie Van Gijsel +1 781 296
1143Sandra Cauwenberghs +32 495 58 46 63 ir@glpg.com |
Forward-looking statementsThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. These
statements are often, but are not always, made through the use of
words or phrases such as “ongoing,” “will,” and “may” as well
similar expressions. Forward-looking statements contained herein
include, but are not limited to, statements regarding the announced
leadership transition and changes in our Executive Committee and
key personnel. These forward-looking statements are subject to
risks, uncertainties and other factors that could cause actual
results to differ materially from those referred to in the
forward-looking statements and, therefore, the reader should not
place undue reliance on them. These risks, uncertainties and other
factors include, without limitation, the possibility that Galapagos
will encounter challenges retaining or attracting talent, that our
leadership transition may be disruptive to our business operations,
risks related to our ability to effectively transfer knowledge
during this period of transition, and those risks and uncertainties
identified in our Annual Report on Form 20-F for the year ended 31
December 2022 and our subsequent filings with the SEC. The
forward-looking statements contained herein are based on
management’s current expectations and beliefs and speak only as of
the date hereof, and Galapagos makes no commitment to update or
publicly release any revisions to forward-looking
statements in order to reflect new information
or subsequent events, circumstances or changes in
expectations, unless specifically required by law or
regulation.
1 Throughout this press release, ‘Dr. Paul
Stoffels’ should be read as ‘Dr. Paul Stoffels, acting via Stoffels
IMC BV’
- PR CFO COO Appointment_ENG_Final
Galapagos (EU:GLPG)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Galapagos (EU:GLPG)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024